Related Experiment Video

Updated: Jul 18, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Molecularly targeted therapy in renal cell carcinoma: where do we go from here?

Brian I Rini1

  • 1Cleveland Clinic Taussig Cancer Center, Department of Solid Tumor Oncology and Urology, 9500 Euclid Avenue/Desk R35, Cleveland, OH 44195, USA. rinib2@ccf.org

Expert Review of Anticancer Therapy
|December 22, 2006
PubMed

Insights

Targeting the vascular endothelial growth factor pathway offers new treatments for metastatic renal cell carcinoma. This review discusses current therapies, clinical data, and future strategies for this complex cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Renal cell carcinoma (RCC) exhibits an angiogenic phenotype driven by vascular endothelial growth factor (VEGF) pathway activation.
  • VEGF pathway dysregulation is a key mechanism in the development and progression of metastatic RCC.
  • Targeting the VEGF pathway has become a cornerstone in the treatment of advanced kidney cancer.

Purpose of the Study:

  • To review current therapeutic strategies targeting the VEGF pathway in metastatic renal cell carcinoma (mRCC).
  • To present key clinical data for these emerging treatments.
  • To discuss considerations for future drug development and clinical application in mRCC.

Main Methods:

  • Review of clinical data and published literature on VEGF pathway inhibitors in mRCC.
  • Analysis of therapeutic strategies, including timing, choice of initial therapy, and role of cytoreductive nephrectomy.
  • Discussion of toxicity profiles and ongoing challenges in mRCC treatment.

Main Results:

  • Several therapeutic strategies targeting the VEGF pathway are clinically relevant in mRCC.
  • Key clinical data supporting these approaches are presented.
  • The article highlights the efficacy of various agents in managing metastatic disease.

Conclusions:

  • VEGF pathway inhibitors represent significant advancements in mRCC treatment.
  • Further research is needed to optimize treatment sequencing, combination therapies, and management of toxicities.
  • Strategic development of novel agents and treatment paradigms is crucial for improving patient outcomes in mRCC.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.